Search Within

Martin Stuart Tallman

Formats
  1. Journal Article (320)
  2. Meeting Abstract (280)
  3. Review (19)
  4. Editorial (9)
  5. Book Section (8)
  6. Research Letter (8)
  7. Guidelines (6)
  8. Correspondence (1)
Groups
  1. Adult Leukemia (651)
  2. Center for Hematologic Malignancies (651)
  3. Department of Medicine (651)
  4. Hematologic Malignancies, Division of (651)
  5. GSK Faculty (164)
  6. Executive Committee, Center for Hematologic Malignancies (156)

More Groups

People
  1. Ross Levine (131)
  2. Eytan Stein (115)
  3. Jae Park (80)
  4. Omar Abdel-Wahab (68)
  5. Sean Devlin (65)
  6. Dan Douer (50)

More People

Years
  1. 2025 (3)
  2. 2024 (9)
  3. 2023 (10)
  4. 2022 (26)
  5. 2021 (45)
  6. 2020 (51)

More Years

Publications
  1. Blood (274)
  2. Journal of Clinical Oncology (41)
  3. Leukemia Research (27)
  4. Blood Advances (26)
  5. Leukemia and Lymphoma (26)
  6. Haematologica (24)

More Publications

Publishers
  1. American Society of Hematology (300)
  2. Elsevier Inc. (43)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (38)
  5. Taylor & Francis Group (28)
  6. Elsevier Ltd (27)

More Publishers

Results (651)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II randomized trial of gilteritinib vs midostaurin in newly diagnosed FLT3 mutated acute myeloid leukemia (AML)
    Meeting Abstract

    Luger, S. M.; Sun, Z.; Loghavi, S.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Pratz, K. W.; Litzow, M.
    Blood (2019)

    Fulltext@MSK | Save
  • Acute leukemia with lineage infidelity: Mixed phenotype AML exhibits a distinct immunophenotype with clinical features overlapping mixed phenotype acute leukemia
    Meeting Abstract

    Kresch, M. P.; Xiao, W.; Menghrajani, K.; Famulare, C.; Patel, M. A.; Baik, J.; Roshal, M.; Levine, R. L.; Tallman, M. S.; Glass, J. L.
    Blood (2019)

    Fulltext@MSK | Save
  • Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia patients at first relapse: A multi-center outcomes analysis
    Meeting Abstract

    Hu, R.; Wei, W.; Gonter-Aubin, K.; Pinilla Ibarz, J.; Kabel, C. C.; Mato, A. R.; Madanat, Y. F.; Khajavian, S.; Shadman, M.; Hanlon, A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome: Updated enrollment of a phase 1 dose escalation and expansion study
    Meeting Abstract

    Foran, J. M.; DiNardo, C. D.; Watts, J. M.; Stein, E. M.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stein, A.; Stone, R. M.; Patel, P. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • De novo myelodysplastic syndromes in patients 20-50 years old characterized by frequent mutations in TP53 and transcription-related genes
    Meeting Abstract

    Epstein-Peterson, Z. D.; Spitzer, B.; McCarter, J.; McGovern, E.; Levine, R. L.; Tallman, M. S.
    Blood (2019)

    Fulltext@MSK | Save
  • Pegaspargase can safely be administered in adults age 40 and older with acute lymphoblastic leukemia
    Meeting Abstract

    Daley, R. J.; Rajeeve, S.; Kabel, C. C.; Pappacena, J. J.; Stump, S. E.; Lavery, J. A.; Tallman, M. S.; Geyer, M. B.; Park, J. H.
    Blood (2019)

    Fulltext@MSK | Save
  • Combined venetoclax and hypomethylating agent (HMA) therapy induces high response rates in patients with myelodysplastic syndrome including patients previously failing HMA
    Meeting Abstract

    Ball, B. J.; Famulare, C.; Stein, E. M.; Tallman, M. S.; Gill, S. I.; Manning, B. M.; Koprivnikar, J.; McCloskey, J.; Testi, R.; Al Ali, N.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Impact of pre-transplant measurable residual disease on relapse incidence and progression-free survival in older AML/MDS patients following allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Lin, R. J.; Elko, T. A.; Devlin, S. M.; Perales, M. A.; Papadopoulos, E. B.; Castro-Malaspina, H.; Gyurkocza, B.; Shaffer, B. C.; Tamari, R.; Tallman, M.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Complex polyclonal resistance mechanisms to ivosidenib monotherapy in IDH1-mutant relapsed or refractory acute myeloid leukemia revealed by single cell sequencing analyses
    Meeting Abstract

    Wang, H.; Choe, S.; DiNardo, C. D.; Stein, E. M.; de Botton, S.; Fathi, A. T.; Tallman, M. S.; Kantarjian, H. M.; Stone, R. M.; Quek, L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Superior survival with post-remission pediatric-inspired chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in adolescents and young adults with ph-negative acute lymphoblastic leukemia in first complete remission: Comparison of CALGB 10403 to patients reported to the CIBMTR
    Meeting Abstract

    Wieduwilt, M. J.; Stock, W.; Advani, A. S.; Luger, S. M.; Larson, R. A.; Tallman, M. S.; Appelbaum, F. R.; Zhang, M. J.; Bo-Subait, K.; Sandmaier, B. M.; more...
    Blood (2019)

    Fulltext@MSK | Save